Single Nucleotide Polymorphisms (SNPs) of FCγRIIA and FCγRIIIA in Patients with Diffuse Large B-Cell Lymphoma Have No Impact On Treatment Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP with and without Rituximab: Results From the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymhoma Study Group (DSHNHL)

被引：0
|
作者：
Ahlgrimm, Manfred
Regitz, Evi [1 ]
Preuss, Klaus-Dieter [1 ]
Grass, Sandra
Poeschel, Viola [2 ]
Kreuz, Markus [3 ]
Pfreundschuh, Michael
机构：
[1] Univ Saarland, Sch Med, Jose Carreras Ctr Immuno & Gene Therapy, Dept Internal Med 1, D-6650 Homburg, Germany
[2] DSHNHL, Homburg, Saar, Germany
[3] IMISE, Leipzig, Germany
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1521 / 1521
页数：1
相关论文
共 50 条
  • [1] FCγRIIIA and FCγRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma
    Mitrovic, Zdravko
    Aurer, Igor
    Radman, Ivo
    Ajdukovic, Radmila
    Sertic, Jadranka
    Labar, Boris
    HAEMATOLOGICA, 2007, 92 (07) : 998 - 999
  • [2] SEX-SPECIFIC EFFECTS OF RITUXIMAB ON TREATMENT OUTCOME OF ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE ANALYSIS OF THE RICOVER-60 TRIAL OF THE GERMAN HIGH-GRADE NON-HODGKIN LYMPHOMA STUDY GROUP (DSHNHL)
    Murawski, N.
    Schubert, J.
    Zeynalova, S.
    Poeschel, V.
    Borchmann, P.
    Ho, A. D.
    Nickenig, C.
    Wessendorf, S.
    Metzner, B.
    Loeffler, M.
    Pfreundschuh, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 436 - 436
  • [3] Response adapted assignment of the number of chemotherapy cycles for the treatment of patients with Diffuse Large B-cell Lymphoma (DLBCL) is not justified: Results of the RICOVER-60 trial of the German high-grade non-hodgkin lymphoma study group (DSHNHL)
    Schubert, J.
    Ziepert, M.
    Lengfelder, E.
    Mohren, M.
    Peter, N.
    Reiser, M.
    Clemens, M.
    Nickenig, C.
    Bokemeyer, C.
    Ho, A. D.
    Eimermacher, H.
    Truemper, L.
    Hoffmann, M.
    Mertelsmann, R.
    Metzner, B.
    Mergenthaler, H. -G.
    Liersch, R.
    Duehrsen, U.
    Balleisen, L.
    Hartmann, F.
    Poeschel, V.
    Schmitz, N.
    Loeffler, M.
    Pfreundschuh, M.
    ONKOLOGIE, 2008, 31 : 120 - 120
  • [4] Response adapted assignment of the number of chemotherapy cycles for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) is not justified: Results of the RICOVER-60 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL)
    Schubert, Joerg
    Ziepert, Marita
    Lengfelder, Eva
    Mohren, Martin
    Peter, Norma
    Reiser, Marcel
    Clemens, Michael
    Nickenig, Christina
    dewit, Maike
    Ho, Anthony
    Eimermacher, Hartmut
    Truemper, Lorenz
    Hoffmann, Martin
    Mertelsmann, Roland
    Metzner, Bernd
    Mergenthaler, Hans-Guenther
    Liersch, Ruediger
    Duehrsen, Ulrich
    Balleisen, Leopold
    Hartmann, Frank
    Poeschel, Viola
    Schmitz, Norbert
    Loeffler, Markus
    Pfreundschuh, Michael
    BLOOD, 2007, 110 (11) : 242A - 242A
  • [5] Six, not eight cycles of bi-weekly CHOP with rituximab (RCHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the RICOVER-60 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL).
    Pfreundschuh, M
    Kloess, M
    Schmits, R
    Zeynalova, S
    Lengfelder, E
    Franke, A
    Steinhauer, H
    Reiser, M
    Clemens, M
    Nickenig, C
    de Wit, M
    Hoffmann, M
    Mertelsmann, R
    Metzner, B
    Ho, A
    Truemper, L
    Eimermacher, H
    Mergenthaler, H
    Liersch, R
    Duehrsen, U
    Balleisen, L
    Hartmann, F
    Poeschel, V
    Schmitz, N
    Loeffler, M
    BLOOD, 2005, 106 (11) : 9A - 9A
  • [6] Six vs. eight cycles of bi-weekly CHOP-14 with or without rituximab for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the completed RICOVER-60 trial of the german high-grade non-Hodgkin lymphoma study group (DSHNHL).
    Pfreundschuh, Michael
    Kloess, Marita
    Zeynalova, Samira
    Lengfelder, Eva
    Franke, Astrid
    Reiser, Marcel
    Steinhauer, Hjalmar
    Clemens, Michael
    Nickenig, Christina
    de Wit, Maike
    Metzner, Bernd
    Hensel, Manfred
    Mergenthaler, Hans-Guenther
    Liersch, Ruediger
    Duehrsen, Ulrich
    Balleisen, Leopold
    Engelhardt, Monika
    Poeschel, Viola
    Schubert, Joerg
    Truemper, Lorenz
    Schmitz, Norbert
    Loeffler, Markus
    BLOOD, 2006, 108 (11) : 64A - 65A
  • [7] The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab
    Ahlgrimm, Manfred
    Pfreundschuh, Michael
    Kreuz, Markus
    Regitz, Evi
    Preuss, Klaus-Dieter
    Bittenbring, Joerg
    BLOOD, 2011, 118 (17) : 4657 - 4662
  • [8] The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients
    Rozman, Samo
    Novakovic, Srdjan
    Grabnar, Iztok
    Cerkovnik, Petra
    Novakovic, Barbara Jezersek
    ONCOLOGY LETTERS, 2016, 11 (05) : 3332 - 3336
  • [9] Six or eight cycles of CHOP plus rituximab for elderly patients with diffuse large B-cell lymphoma: Updated results of the RICOVER-60 trial
    Muneer, Sabeeha
    Cunningham, Sonia
    CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (01): : 14 - 15
  • [10] Dose-dense rituximab improves outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL): Results of the DENSE-R-CHOP-14 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL)
    Pfreundschuh, Michael
    Zeynalova, Samira
    Poeschel, Viola
    Haenel, Mathias
    Schmitz, Norbert
    Hensel, Manfred
    Reiser, Marcel
    Loeffler, Markus
    Schubert, Joerg
    BLOOD, 2007, 110 (11) : 243A - 243A
12345